Early trial tests 'Off-the-Shelf' cell therapy for tough leukemia cases
NCT ID NCT07470073
Summary
This early-phase study is testing a new type of cell therapy called CT1190B, a 'universal' CAR-T, for patients aged 12-75 whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments. The main goals are to find a safe and effective dose and to see how the modified cells behave in the body. It is a small study enrolling 18-36 participants to gather initial safety and response data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.